RARE DISEASE
Oculopharyngeal muscular dystrophy
Oculopharyngeal muscular dystrophy
Oculopharyngeal muscular dystrophy
Synonyms: OPMD
Synonyms: OPMD
Synonyms: OPMD
Drug discovery
3
drugs
With orphan designations
Overview
Oculopharyngeal muscular dystrophy (OPMD) is a rare autosomal dominant disorder caused by PABPN1 gene mutations, characterized by late-onset ptosis, dysphagia, and proximal limb weakness. Symptoms typically emerge in the 40s–50s, progressing slowly. Diagnosis involves genetic testing and clinical evaluation. Management focuses on symptom relief through surgical interventions (e.g., blepharoplasty, cricopharyngeal myotomy) and supportive therapies [1][7][18]. Life expectancy is near-normal with proper care, though complications like aspiration pneumonia pose risks [7][19].
Burden
Physical: Progressive dysphagia increases aspiration and malnutrition risks; mobility loss necessitates assistive devices [4][6][9].
Psychosocial: Chronic fatigue, pain, and social isolation due to visible ptosis and swallowing difficulties [4][13].
Economic: Requires lifelong multidisciplinary care (neurology, ENT, nutrition) [9][19].
Therapies
Surgical: Ptosis correction (frontalis sling), dysphagia management (cricopharyngeal myotomy, Botox injections) [6][8][18].
Supportive: Speech therapy, gastrostomy for severe dysphagia; physiotherapy for limb weakness [6][8][9].
Investigational: RNA replacement, AAV-mediated gene therapy, and trehalose (Phase IIb trial) [3][12][17].
Categories: rare developmental anomalies during embryogenesis, rare genetic diseases, rare neurological diseases, rare ophthalmic disorders
Research Papers
161 drug discovery papers related to Oculopharyngeal muscular dystrophy, with 5 first-in-class and 0 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
161 drug discovery papers related to Oculopharyngeal muscular dystrophy, with 5 first-in-class and 0 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
2026-06-20 | Collagen VI is a fibrosis-associated signal disrupting muscle regeneration across distinct human myopathies.
Muscle fibrosis is a major driver of progression in diverse myopathies, yet the conserved molecular mediators of this process in humans remain poorly defined. Here, we identify collagen VI as a common regeneration-impairing extracellular matrix (ECM) component across three distinct human myopathies: Duchenne Muscular Dystrophy (DMD), Oculopharyngeal Muscular Dystrophy (OPMD), and Inclusion Body Myositis (IBM). Proteomic profiling of fibrotic biopsies reveals consistent upregulation of collagen VI and laminin γ1, alongside disease-specific alterations. Fibroadipogenic progenitors (FAPs) are the predominant source of these ECM components, including collagen VI and laminin γ1. Functionally, xenotransplantation of patient-derived FAPs into regenerating mouse muscle induces localized collagen deposition, myofiber atrophy, and depletion of Pax7⁺ muscle stem cells. Mechanistic assays demonstrate that FAP-derived collagen VI is sufficient to impair myogenic fusion, while silencing COL6 in patient FAPs restores fusion capacity, directly linking pathological collagen VI deposition to regeneration failure. Our findings uncover collagen VI as a conserved effector of fibrosis and stem cell niche disruption in human myopathies, positioning it as a potential therapeutic target across genetically and clinically distinct muscle diseases.
2026-06-16 | Distinct roles of IDR and CCD domains control PABPN1 aggregation and enable therapeutic rescue
Abstract PABPN1 is a multifunctional protein whose expression is tightly regulated to maintain cellular homeostasis. PABPN1 dysregulation contributes to both common acquired diseases, such as bladder cancer, and rare inherited disorders, including oculopharyngeal muscular dystrophy (OPMD). In OPMD, PABPN1 forms insoluble aggregates that reduce its functional levels, leading to genome-wide shifts in alternative polyadenylation (APA) at 3′-UTRs and disruption of mRNA metabolism, including nuclear export and translation. OPMD is caused by a short alanine expansion at the N-terminus of PABPN1 within an intrinsically disordered region (IDR) followed by a coiled-coil domain (CCD). How these domains contribute to PABPN1 function and aggregation remains unclear. Here, we show that the N-terminal IDR promotes aggregation and modulates protein-protein interactions with longer IDRs suppressing interaction between PABPN1 and its binding partners. We further demonstrate that the CCD has dual functions: its N-terminal domain dictates PABPN1 stability, whereas its C-terminal domain enhances the PABPN1 interactome. We identified a naturally occurring variant lacking exon 1 encoding the IDR and the CCD N-terminal domain (named trPAB). That variant forms a stable, non-aggregating protein isoform. Interactome analysis and structural modeling indicate improved molecular function by restoring PABPN1 activity, APA profiles, and cellular phenotypes in OPMD and bladder cancer models. Importantly, delivery of trPAB via Adeno-associated viral vector in an OPMD mouse model improves muscle histopathology, supporting its potential as a therapeutic strategy. A mechanistic basis of a novel gene therapy approach for OPMD Top panel: A schematic presentation of three PABPN1 variant functional states. Left: the normal full-length protein interacts with key RNA binding protein (RBP) partners supporting normal cellular function. Middle: A pathogenic full-length alanine-expanded PABPN1 leads to protein aggregation, resulting in limited interactors, dysfunctional complexes and impaired cellular processes. Right: a truncated natural variant (trPAB), not associated with OPMD pathology, shows enhanced stability and reduced aggregation, suggesting a potential protective or “super functional” profile. The bottom panel translates these mechanistic insights into therapeutic strategy. In cell models, expression of trPAB is associated with reduced protein aggregation, restoration of normal cellular function, and improved myogenesis. These effects are recapitulated in a relevant animal model of OPMD, where trPAB treatment leads to decreased aggregation, functional recovery, and reversal of muscle atrophy. Our study supports the rationale for leveraging a stabilized PABPN1 variant as a novel gene therapy approach to counteract aggregation-driven pathology in OPMD. Highlights The central coiled-coil domain (CCD) of PABPN1 has two opposing functions: its N-terminal region stabilizes the protein, while its C-terminal region promotes stability but hampers aggregation. At the N-terminus, an intrinsically disordered region (IDR) acts as a gatekeeper for protein interactions. The alanine tract, including its pathogenic expansion, restricts this interactome, limiting PABPN1 binding capacity. We identified a naturally occurring PABPN1 isoform, trPAB, which lacks exon 1, including the IDR and the N-terminal portion of the CCD. trPAB forms a stable and functional protein and exerts beneficial effects in muscle cells. Functionally, trPAB rescues key cellular phenotypes in bladder cancer cells and reverses nuclear aggregation and muscle atrophy in a mouse model of OPMD.
2026-04-30 | Molecular and therapeutic effects of bioactive compounds-incorporated mucoadhesive buccal patch targeting oral potentially malignant disorders.
Oral potentially malignant disorders (OPMD) are associated with high risk of progression to oral squamous cell carcinoma (OSCC) and remain difficult to manage, due to limited effective localized therapies, underscoring the urgent need for novel, targeted drug delivery systems. A mucoadhesive buccal patch loaded bioactive components such as isotretinoin, bromelain, and limonene (IBL patch) was fabricated and evaluated for its anticancer potential against OPMD-associated OSCC. The cytotoxic study demonstrated that the IBL patch significantly reduced CAL-27 cells viability and found IC50 value around 650 μg/mL, while exhibiting minimal cytotoxicity toward human gingival fibroblast (HGF) cells, indicating selective anticancer activity. In comparison to HGF cells, the IBL patch significantly reduced the migration and invasion of CAL-27 cells. Colony formation assays further confirmed that the IBL patch significantly suppressed the long-term proliferative and clonogenic potential of CAL-27 cells, without affecting HGF cells division. Genotoxicity analysis revealed increased micronucleus formation in CAL-27 cells, suggesting DNA damage-mediated apoptotic induction. Then IBL patch showed molecular effects by suppressing EMT and fibrosis associated TGF-β/SMAD signaling, inhibiting inflammatory (NF-κB), Wnt/β-Catenin pathways and Cytokeratin 17 (CK-17) and restoring epithelial identity through E-Cadherin and CK-18 upregulation. Furthermore, pathway analysis in both monolayer and co-culture inflammatory models demonstrated that the IBL patch effectively suppressed LPS-induced inflammatory markers, including TGF-β, MMP-2, IL-6, and TNF-α expression. Oral acute toxicity testing (OECD 423) confirmed safety of the IBL patch, with no mortality or adverse effects up to 2000 mg/kg (LD₅₀ > 2000 mg/kg; GHS Category 5). Collectively, these findings highlights that the IBL mucoadhesive buccal patch has therapeutic potential against OPMD and controlling pathological epithelial remodeling.
2026-06-20 | Collagen VI is a fibrosis-associated signal disrupting muscle regeneration across distinct human myopathies.
Muscle fibrosis is a major driver of progression in diverse myopathies, yet the conserved molecular mediators of this process in humans remain poorly defined. Here, we identify collagen VI as a common regeneration-impairing extracellular matrix (ECM) component across three distinct human myopathies: Duchenne Muscular Dystrophy (DMD), Oculopharyngeal Muscular Dystrophy (OPMD), and Inclusion Body Myositis (IBM). Proteomic profiling of fibrotic biopsies reveals consistent upregulation of collagen VI and laminin γ1, alongside disease-specific alterations. Fibroadipogenic progenitors (FAPs) are the predominant source of these ECM components, including collagen VI and laminin γ1. Functionally, xenotransplantation of patient-derived FAPs into regenerating mouse muscle induces localized collagen deposition, myofiber atrophy, and depletion of Pax7⁺ muscle stem cells. Mechanistic assays demonstrate that FAP-derived collagen VI is sufficient to impair myogenic fusion, while silencing COL6 in patient FAPs restores fusion capacity, directly linking pathological collagen VI deposition to regeneration failure. Our findings uncover collagen VI as a conserved effector of fibrosis and stem cell niche disruption in human myopathies, positioning it as a potential therapeutic target across genetically and clinically distinct muscle diseases.
2026-06-16 | Distinct roles of IDR and CCD domains control PABPN1 aggregation and enable therapeutic rescue
Abstract PABPN1 is a multifunctional protein whose expression is tightly regulated to maintain cellular homeostasis. PABPN1 dysregulation contributes to both common acquired diseases, such as bladder cancer, and rare inherited disorders, including oculopharyngeal muscular dystrophy (OPMD). In OPMD, PABPN1 forms insoluble aggregates that reduce its functional levels, leading to genome-wide shifts in alternative polyadenylation (APA) at 3′-UTRs and disruption of mRNA metabolism, including nuclear export and translation. OPMD is caused by a short alanine expansion at the N-terminus of PABPN1 within an intrinsically disordered region (IDR) followed by a coiled-coil domain (CCD). How these domains contribute to PABPN1 function and aggregation remains unclear. Here, we show that the N-terminal IDR promotes aggregation and modulates protein-protein interactions with longer IDRs suppressing interaction between PABPN1 and its binding partners. We further demonstrate that the CCD has dual functions: its N-terminal domain dictates PABPN1 stability, whereas its C-terminal domain enhances the PABPN1 interactome. We identified a naturally occurring variant lacking exon 1 encoding the IDR and the CCD N-terminal domain (named trPAB). That variant forms a stable, non-aggregating protein isoform. Interactome analysis and structural modeling indicate improved molecular function by restoring PABPN1 activity, APA profiles, and cellular phenotypes in OPMD and bladder cancer models. Importantly, delivery of trPAB via Adeno-associated viral vector in an OPMD mouse model improves muscle histopathology, supporting its potential as a therapeutic strategy. A mechanistic basis of a novel gene therapy approach for OPMD Top panel: A schematic presentation of three PABPN1 variant functional states. Left: the normal full-length protein interacts with key RNA binding protein (RBP) partners supporting normal cellular function. Middle: A pathogenic full-length alanine-expanded PABPN1 leads to protein aggregation, resulting in limited interactors, dysfunctional complexes and impaired cellular processes. Right: a truncated natural variant (trPAB), not associated with OPMD pathology, shows enhanced stability and reduced aggregation, suggesting a potential protective or “super functional” profile. The bottom panel translates these mechanistic insights into therapeutic strategy. In cell models, expression of trPAB is associated with reduced protein aggregation, restoration of normal cellular function, and improved myogenesis. These effects are recapitulated in a relevant animal model of OPMD, where trPAB treatment leads to decreased aggregation, functional recovery, and reversal of muscle atrophy. Our study supports the rationale for leveraging a stabilized PABPN1 variant as a novel gene therapy approach to counteract aggregation-driven pathology in OPMD. Highlights The central coiled-coil domain (CCD) of PABPN1 has two opposing functions: its N-terminal region stabilizes the protein, while its C-terminal region promotes stability but hampers aggregation. At the N-terminus, an intrinsically disordered region (IDR) acts as a gatekeeper for protein interactions. The alanine tract, including its pathogenic expansion, restricts this interactome, limiting PABPN1 binding capacity. We identified a naturally occurring PABPN1 isoform, trPAB, which lacks exon 1, including the IDR and the N-terminal portion of the CCD. trPAB forms a stable and functional protein and exerts beneficial effects in muscle cells. Functionally, trPAB rescues key cellular phenotypes in bladder cancer cells and reverses nuclear aggregation and muscle atrophy in a mouse model of OPMD.
2026-04-30 | Molecular and therapeutic effects of bioactive compounds-incorporated mucoadhesive buccal patch targeting oral potentially malignant disorders.
Oral potentially malignant disorders (OPMD) are associated with high risk of progression to oral squamous cell carcinoma (OSCC) and remain difficult to manage, due to limited effective localized therapies, underscoring the urgent need for novel, targeted drug delivery systems. A mucoadhesive buccal patch loaded bioactive components such as isotretinoin, bromelain, and limonene (IBL patch) was fabricated and evaluated for its anticancer potential against OPMD-associated OSCC. The cytotoxic study demonstrated that the IBL patch significantly reduced CAL-27 cells viability and found IC50 value around 650 μg/mL, while exhibiting minimal cytotoxicity toward human gingival fibroblast (HGF) cells, indicating selective anticancer activity. In comparison to HGF cells, the IBL patch significantly reduced the migration and invasion of CAL-27 cells. Colony formation assays further confirmed that the IBL patch significantly suppressed the long-term proliferative and clonogenic potential of CAL-27 cells, without affecting HGF cells division. Genotoxicity analysis revealed increased micronucleus formation in CAL-27 cells, suggesting DNA damage-mediated apoptotic induction. Then IBL patch showed molecular effects by suppressing EMT and fibrosis associated TGF-β/SMAD signaling, inhibiting inflammatory (NF-κB), Wnt/β-Catenin pathways and Cytokeratin 17 (CK-17) and restoring epithelial identity through E-Cadherin and CK-18 upregulation. Furthermore, pathway analysis in both monolayer and co-culture inflammatory models demonstrated that the IBL patch effectively suppressed LPS-induced inflammatory markers, including TGF-β, MMP-2, IL-6, and TNF-α expression. Oral acute toxicity testing (OECD 423) confirmed safety of the IBL patch, with no mortality or adverse effects up to 2000 mg/kg (LD₅₀ > 2000 mg/kg; GHS Category 5). Collectively, these findings highlights that the IBL mucoadhesive buccal patch has therapeutic potential against OPMD and controlling pathological epithelial remodeling.
Access all drug discovery articles and probability of success in trials forecasts:
Access all drug discovery articles and probability of success in trials forecasts:
Drug Discovery Landscape
3 orphan drug designations for Oculopharyngeal muscular dystrophy.
3 orphan drug designations for Oculopharyngeal muscular dystrophy.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
genetically modified, non-self replicating Adeno-Associated Virus serotype 9 expressing shRNA to knock down mutant PABP1 as well as a codon optimized, shRNA-insensitive, wildtype PABN1 | gene therapies | FDA | 2018-01-08 | — | Benitec Biopharma Limited |
Genetically modified adeno-associated viral vector serotype 9 expressing shRNA as well as a codon-optimized shRNA-insensitive wildtype PABPN1 | gene therapies | EMA | 2017-01-12 | — | Clinipace GmbH |
Trehalose | small molecules | EMA | 2015-05-21 | — | FGK Representative Service GmbH |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.